|
1
|
Hesse A, Brändle E, Wilbert D, Köhrmann KU
and Alken P: Study on the prevalence and incidence of urolithiasis
in Germany comparing the years 1979 vs. 2000. Eur Urol. 44:709–713.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Saigal CS, Joyce G and Timilsina AR;
Urologic Diseases in America Project: Direct and indirect costs of
nephrolithiasis in an employed population: Opportunity for disease
management? Kidney Int. 68:1808–1814. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Turney BW, Reynard JM, Noble JG and
Keoghane SR: Trends in urological stone disease. BJU Int.
109:1082–1087. 2012. View Article : Google Scholar
|
|
4
|
Knoll T, Schubert AB, Fahlenkamp D,
Leusmann DB, Wendt-Nordahl G and Schubert G: Urolithiasis through
the ages: Data on more than 200,000 urinary stone analyses. J Urol.
185:1304–1311. 2011. View Article : Google Scholar
|
|
5
|
Yang X, Zhang C, Qi S, Zhang Z, Shi Q, Liu
C, Yang K, Du E, Li N, Shi J and Xu Y: Multivariate analyses of
urinary calculi composition: A 13-year single-center study. J Clin
Lab Anal. 30:873–879. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Milliner DS, Wilson DM and Smith LH:
Phenotypic expression of primary hyperoxaluria: Comparative
features of types I and II. Kidney Int. 59:31–36. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pearle MS, Calhoun EA and Curhan GC;
Urologic Diseases of America Project: Urologic diseases in America
project: Urolithiasis. J Urol. 173:848–857. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kumar S, Sigmon D, Miller T, Carpenter B,
Khan S, Malhotra R, Scheid C and Menon M: A new model of
nephrolithiasis involving tubular dysfunction/injury. J Urol.
146:1384–1389. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim HH, Kwak C, Jeong BC and Kim SW:
Effect of oxalate on the growth of renal tubular epithelial cells.
J Endourol. 16:261–264. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fujii Y, Okada A, Yasui T, Niimi K,
Hamamoto S, Hirose M, Kubota Y, Tozawa K, Hayashi Y and Kohri K:
Effect of adiponectin on kidney crystal formation in metabolic
syndrome model mice via inhibition of inflammation and apoptosis.
PLoS One. 8:e613432013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Khan SR: Reactive oxygen species as the
molecular modulators of calcium oxalate kidney stone formation:
Evidence from clinical and experimental investigations. J Urol.
189:803–811. 2013. View Article : Google Scholar
|
|
12
|
Taguchi K, Okada A, Hamamoto S, Iwatsuki
S, Naiki T, Ando R, Mizuno K, Tozawa K, Kohri K and Yasui T:
Proinflammatory and metabolic changes facilitate renal crystal
deposition in an obese mouse model of metabolic syndrome. J Urol.
194:1787–1796. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rovin BH and Phan LT: Chemotactic factors
and renal inflammation. Am J Kidney Dis. 31:1065–1084. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wesson JA, Johnson RJ, Mazzali M,
Beshensky AM, Stietz S, Giachelli C, Liaw L, Alpers CE, Couser WG,
Kleinman JG and Hughes J: Osteopontin is a critical inhibitor of
calcium oxalate crystal formation and retention in renal tubules. J
Am Soc Nephrol. 14:139–147. 2003. View Article : Google Scholar
|
|
15
|
Khan SR and Kok DJ: Modulators of urinary
stone formation. Front Biosci. 9:1450–1482. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Umekawa T, Chegini N and Khan SR: Oxalate
ions and calcium oxalate crystals stimulate MCP-1 expression by
renal epithelial cells. Kidney Int. 61:105–112. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Morimoto J, Kon S, Matsui Y and Uede T:
Osteopontin; as a target molecule for the treatment of inflammatory
diseases. Curr Drug Targets. 11:494–505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Novelle MG, Ali A, Diéguez C, Bernier M
and de Cabo R: Metformin: A hopeful promise in aging research. Cold
Spring Harb Perspect Med. 6:a0259322016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang X, Ding H, Qin Z, Zhang C, Qi S,
Zhang H, Yang T, He Z, Yang K, Du E, et al: Metformin prevents
renal stone formation through an antioxidant mechanism in vitro and
in vivo. Oxid Med Cell Longev. 2016.4156075:2016.
|
|
20
|
Cavaglieri RC, Day RT, Feliers D and
Abboud HE: Metformin prevents renal interstitial fibrosis in mice
with unilateral ureteral obstruction. Mol Cell Endocrinol.
412:116–122. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Park HK, Jeong BC, Sung MK, Park MY, Choi
EY, Kim BS, Kim HH and Kim JI: Reduction of oxidative stress in
cultured renal tubular cells and preventive effects on renal stone
formation by the bioflavonoid quercetin. J Urol. 179:1620–1626.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Umekawa T, Iguchi M, Uemura H and Khan SR:
Oxalate ions and calcium oxalate crystal-induced up-regulation of
osteopontin and monocyte chemoattractant protein-1 in renal
fibroblasts. BJU Int. 98:656–660. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang MY, Chaturvedi LS, Koul S and Koul
HK: Oxalate stimulates IL-6 production in HK-2 cells, a line of
human renal proximal tubular epithelial cells. Kidney Int.
68:497–503. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li Y and McMartin KE: Strain differences
in urinary factors that promote calcium oxalate crystal formation
in the kidneys of ethylene glycol-treated rats. Am J Physiol Renal
Physiol. 296:F1080–F1087. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Green ML, Hatch M and Freel RW: Ethylene
glycol induces hyperoxaluria without metabolic acidosis in rats. Am
J Physiol Renal Physiol. 289:F536–F543. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Khan SR, Johnson JM, Peck AB, Cornelius JG
and Glenton PA: Expression of osteopontin in rat kidneys: Induction
during ethylene glycol induced calcium oxalate nephrolithiasis. J
Urol. 168:1173–1181. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Quaile MP, Melich DH, Jordan HL, Nold JB,
Chism JP, Polli JW, Smith GA and Rhodes MC: Toxicity and
toxicokinetics of metformin in rats. Toxicol Appl Pharmacol.
243:340–347. 2010. View Article : Google Scholar
|
|
28
|
Matveyenko AV, Dry S, Cox HI, Moshtaghian
A, Gurlo T, Galasso R, Butler AE and Butler PC: Beneficial
endocrine but adverse exocrine effects of sitagliptin in the human
islet amyloid polypeptide transgenic rat model of type 2 diabetes:
Interactions with metformin. Diabetes. 58:1604–1615. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
30
|
Taguchi K, Okada A, Kitamura H, Yasui T,
Naiki T, Hamamoto S, Ando R, Mizuno K, Kawai N, Tozawa K, et al:
Colony-stimulating factor-1 signaling suppresses renal crystal
formation. J Am Soc Nephrol. 25:1680–1697. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Taguchi K, Okada A, Yasui T, Kobayashi T,
Ando R, Tozawa K and Kohri K: Pioglitazone, a peroxisome
proliferator activated receptor γ agonist, decreases renal crystal
deposition, oxidative stress and inflammation in hyperoxaluric
rats. J Urol. 188:1002–1011. 2012. View Article : Google Scholar
|
|
32
|
Tsujihata M, Momohara C, Yoshioka I,
Tsujimura A, Nonomura N and Okuyama A: Atorvastatin inhibits renal
crystal retention in a rat stone forming model. J Urol.
180:2212–2217. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Moe OW: Kidney stones: Pathophysiology and
medical management. Lancet. 367:333–344. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vasamsetti SB, Karnewar S, Kanugula AK,
Thatipalli AR, Kumar JM and Kotamraju S: Metformin inhibits
monocyte-to-macrophage differentiation via AMPK-mediated inhibition
of STAT3 activation: Potential role in atherosclerosis. Diabetes.
64:2028–2041. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Matsushita Y, Ogawa D, Wada J, Yamamoto N,
Shikata K, Sato C, Tachibana H, Toyota N and Makino H: Activation
of peroxisome proliferator-activated receptor delta inhibits
streptozotocin-induced diabetic nephropathy through
anti-inflammatory mechanisms in mice. Diabetes. 60:960–968. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Grandaliano G, Gesualdo L, Ranieri E,
Monno R, Montinaro V, Marra F and Schena FP: Monocyte chemotactic
peptide-1 expression in acute and chronic human nephritides: A
pathogenetic role in interstitial monocytes recruitment. J Am Soc
Nephrol. 7:906–913. 1996.PubMed/NCBI
|
|
37
|
Umekawa T, Tsuji H, Uemura H and Khan SR:
Superoxide from NADPH oxidase as second messenger for the
expression of osteopontin and monocyte chemoattractant protein-1 in
renal epithelial cells exposed to calcium oxalate crystals. BJU
Int. 104:115–120. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Okada A, Nomura S, Saeki Y, Higashibata Y,
Hamamoto S, Hirose M, Itoh Y, Yasui T, Tozawa K and Kohri K:
Morphological conversion of calcium oxalate crystals into stones is
regulated by osteopontin in mouse kidney. J Bone Miner Res.
23:1629–1637. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Koul S, Khandrika L, Meacham RB and Koul
HK: Genome wide analysis of differentially expressed genes in HK-2
cells, a line of human kidney epithelial cells in response to
oxalate. PLoS One. 7:e438862012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Koul HK, Koul S, Fu S, Santosham V,
Seikhon A and Menon M: Oxalate: From crystal formation to crystal
retention. J Am Soc Nephrol. 10(Suppl 14): S417–S421.
1999.PubMed/NCBI
|
|
41
|
Itoh Y, Yasui T, Okada A, Tozawa K,
Hayashi Y and Kohri K: Preventive effects of green tea on renal
stone formation and the role of oxidative stress in
nephrolithiasis. J Urol. 173:271–275. 2005. View Article : Google Scholar
|
|
42
|
Pearlstein RA, McKay DJJ, Hornak V,
Dickson C, Golosov A, Harrison T, Velez-Vega C and Duca J: Building
new bridges between in vitro and in vivo in early drug discovery:
Where molecular modeling meets systems biology. Curr Top Med Chem.
17:2642–2662. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jaroch K, Jaroch A and Bojko B: Cell
cultures in drug discovery and development: The need of reliable in
vitro-in vivo extrapolation for pharmacodynamics and
pharmacokinetics assessment. J Pharm Biomed Anal. 147:297–312.
2018. View Article : Google Scholar
|
